Balyasny Asset Management
AGIO icon

Balyasny Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Balyasny Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-277,500
Closed -$12.8M – 1376
2018
Q4 		$12.8M Buy
+277,500
New +$17.1M 0.09% 301
2018
Q3 		– Sell
-200,000
Closed -$16.8M – 1627
2018
Q2 		$16.8M Buy
+200,000
New +$17.4M 0.08% 352
2017
Q4 		– Sell
-270,000
Closed -$18M – 2029
2017
Q3 		$18M Buy
+270,000
New +$16.2M 0.07% 343
2017
Q1 		– Sell
-70,000
Closed -$2.92M – 1565
2016
Q4 		$2.92M Buy
+70,000
New +$3.67M 0.02% 819

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Balyasny Asset Management's AGIO Position: Q2 2026 in Review

Balyasny Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 18,009 shares — an estimated $609K sold.

Balyasny Asset Management first reported a position in AGIO in Q3 2015 and held it in 27 quarters. The position peaked at $64.6M in Q4 2017. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Balyasny Asset Management reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 18,009 Agios Pharmaceuticals shares in Q2 2026, an estimated $609K.
  • Balyasny Asset Management first reported a position in Agios Pharmaceuticals in Q3 2015 and held it in 27 quarters.
  • Balyasny Asset Management's Agios Pharmaceuticals position peaked at $64.6M in Q4 2017.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.